About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
Key Information
We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.
Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies.
What we do
We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how and talented people.
Pharmaceuticals
Our pharmaceuticals business has a broad portfolio of innovative and established medicines in respiratory, HIV, immuno-inflammation and oncology. We are strengthening our R&D pipeline through a focus on immunology, human genetics and advanced technologies to help us deliver transformational new medicines for patients.
Vaccines
We are the world’s largest vaccines company by revenue, delivering vaccines that help protect people at all stages of life. Our R&D focuses on developing vaccines against infectious diseases that combine high medical need and strong market potential.
Consumer Healthcare
Our world-leading Consumer Healthcare business combines science and consumer insights to create innovative everyday healthcare brands that consumers trust and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements.
In 2019, we completed a transaction with Pfizer to combine our consumer healthcare businesses into a new joint venture that will ultimately be separated via a demerger. This will enable us to create a new global Pharmaceuticals/Vaccines company, and a new world-leading Consumer Healthcare company.
How we do it
Everyone at GSK is focused on our 3 long-term priorities – Innovation, Performance, Trust, all powered by our performance-focused culture.
Innovation
Innovation is at the heart of delivering GSK’s purpose, by using our science to develop better medicines, vaccines, and consumer healthcare products. We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.
-
£4.3bn
adjusted R&D investment in 2020
-
40
new medicines in development at FY 2020
-
17
new vaccines in development at FY 2020
Performance
We deliver growth by investing effectively in our business, developing our people and executing competitively.
-
£34bn
turnover in 2020
-
£9bn
adjusted operating profit in 2020
-
£5.4bn
free cash flow in 2020
-
£4bn
dividends paid in 2020
Trust
We are a responsible company – using our science and technology to address health needs, we are focused on making our products affordable and available and being a modern employer.
-
84%
employee engagement score on our latest employee survey
-
£250m
donated in 2020 to community health programmes
-
1st
in Access to Medicines Index since the assessment began in 2008
